Saturday 17 October 2026
Export TMDX’s income statement to Excel — free account
TransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 20.7%, EPS fell 59.2%, free cash flow fell 87.6% and total debt rose 68.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
70.78
5.74
−7.50%
Follow TMDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 7 | 7 |
+8 more TTM periods Free account |
| 36.28% | 45.22% | 54.24% | 32.48% | ||
| 12.88% | 15.13% | 20.33% | 10.60% | ||
ROIC |
5.62% | 6.64% | 13.65% | 14.97% | |
Return on Tangible Assets |
16.52% | 19.34% | 21.72% | 10.84% | |
Average Days of Receivables |
56.86 | 52.08 | 50.81 | 52.01 | |
Free Cash Flow per Share |
2.29 | 4.40 | 3.93 | 3.54 | |
Free Cash Flow |
79.04 | 151.36 | 133.59 | 120.65 | |
Capital Expenditures |
(66.89) | (68.87) | (59.25) | (57.34) | |
| Other line items | |||||
Cash ROIC |
4.27% | 8.35% | 9.06% | 9.05% | |
Accounts Receivable Turnover |
6.40 | 5.46 | 6.65 | 6.63 | |
Accounts Payable Turnover |
24.60 | 23.93 | 23.51 | 17.79 | |
Inventory Turnover |
5.94 | 5.58 | 5.09 | 4.65 | |
Average Days of Payables |
17.06 | 15.65 | 15.57 | 19.73 | |
Days of Inventory on Hand |
71.56 | 70.00 | 73.52 | 72.22 | |
Tax Rate |
1.09 | 0.92 | 0.77 | (0.01) | |
Research and Development Expense of Revenue |
13.83% | 12.07% | 11.40% | 11.44% | |
Selling, General and Administrative Expense of Revenue |
32.65% | 32.16% | 30.58% | 31.89% | |
Share Based Compensation of Revenue |
5.55% | 5.95% | 6.09% | 6.75% | |
Interest Coverage |
3.84 | 5.40 | 7.88 | 6.85 | |
Operating CF/Net income |
0.96 | 1.28 | 1.01 | 1.94 | |
Depreciation/Fixed assets |
0.10 | 0.09 | 0.08 | 0.08 | |
Capex/Depreciation |
(1.84) | (2.09) | (2.18) | (2.26) | |
Revenue per Share |
19.33 | 18.49 | 17.81 | 16.60 | |
Operating CF per Share |
4.22 | 6.40 | 5.67 | 5.22 | |
Capex per Share |
(1.93) | (2.00) | (1.74) | (1.68) | |
Capex to Sales |
0.10 | 0.11 | 0.10 | 0.10 |
Columns are period end dates